Background: Metabolic syndrome is a clinical condition that deserves special attention because it
puts the individual at high cardiovascular risk, especially heart attack and stroke. Considering precision
medicine, it would be advisable to evaluate the individual cardio-metabolic risk by estimating the coexistence
of risk factors (abdominal obesity, low level of High-Density Lipoprotein Cholesterol, High Triglycerides, and
small dense Low-Density Lipoproteins sub-classes, hypertension, and elevated fasting glycemia), which could
engrave on metabolism increasing cardiovascular mortality.
Objective: To identify genetic and epigenetic biomarkers may assist in the possibility of helping follow-up
strategies and other measures of prevention and in metabolic risk.
Methods: We searched for studies that valued the combination between epigenetic biomarkers and all factors of
Results: Numerous researches have investigated the molecular start of metabolic alterations, focusing on the
epigenetic mark, as methylation of DNA, histone modifications and non.coding RNAs. It has been found that
DNA methylation is the most searched epigenetic sign in the human genome concerning the control of gene expression.
Conclusion: For the screening, diagnosis, and prognosis of metabolic syndrome and the prescription of personalized
medicine, the DNA methylation biomarkers specify for subjects have been recognized as an ensuring
tool. While these results are promising, further investigations are needed to unravel the complicated synergic association
of the genome, epigenome and the situations related to metabolic pathology.